Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem® Therapy for Indications in China
17 déc. 2018 06h00 HE
|
Athersys, Inc.
CLEVELAND, Ohio, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today the extension of HEALIOS K.K.’s (Healios) exclusive period to negotiate an option that would allow...
Athersys Reports Third Quarter 2018 Results
06 nov. 2018 16h05 HE
|
Athersys, Inc.
Management to host conference call at 4:30pm EST today CLEVELAND, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the period ended...
Athersys to Host Third Quarter Financial Results Call
09 oct. 2018 16h00 HE
|
Athersys, Inc.
CLEVELAND, Ohio, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) will release its third quarter 2018 financial results at approximately 4:00 p.m. Eastern Time on Tuesday, November...
Athersys to Present at 2018 Cell & Gene Meeting on the Mesa
24 sept. 2018 06h00 HE
|
Athersys, Inc.
CEO invited to provide corporate overview and speak in two workshops focusing on innovative development initiatives in Japan and advanced manufacturing technologies CLEVELAND, Ohio, Sept. 24, 2018 ...
Athersys Reports Second Quarter 2018 Results
07 août 2018 16h05 HE
|
Athersys, Inc.
CLEVELAND, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended June 30, 2018. Highlights of the second quarter of 2018...
Athersys Makes Important Leadership Hire to Carry Out Its Manufacturing Strategy
03 août 2018 06h00 HE
|
Athersys, Inc.
CLEVELAND, Aug. 03, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced the addition of an experienced manufacturing executive to oversee manufacturing operations and help plan for and...
Athersys Announces Enrollment of First Patient in Masters-2 Phase 3 Study of Multistem® Treatment for Ischemic Stroke
31 juil. 2018 06h00 HE
|
Athersys, Inc.
Pivotal study has received a Special Protocol Assessment (SPA), Fast Track Designation, and Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) ...
Athersys to Host Second Quarter Financial Results Call
10 juil. 2018 16h00 HE
|
Athersys, Inc.
CLEVELAND, July 10, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) will release its second quarter 2018 financial results at approximately 4:00 PM Eastern Time on Tuesday, August 7th, 2018,...
Athersys Announces Expansion of Collaboration With Healios
07 juin 2018 06h00 HE
|
Athersys, Inc.
Healios receives rights to develop and commercialize additional indications and Athersys receives $20 million in license fees, plus potential milestones payments and royalties Discussions extended...
Athersys Announces Expansion of Collaboration With Healios
07 juin 2018 02h00 HE
|
Athersys, Inc.
Healios receives rights to develop and commercialize additional indications and Athersys receives $20 million in license fees, plus potential milestones payments and royalties Discussions extended...